News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Subscribe To Our Newsletter & Stay Updated
